AbbVie and Momenta announce Humira patent licence agreement

Biotech company Momenta has obtained the rights to use AbbVie’s Humira (adalimumab) IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie and Mylan agree Humira licensing deal

18 July 2018 US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

Americas

AbbVie and Samsung Bioepis resolve Humira litigation

9 April 2018 AbbVie has secured another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.

Americas

AbbVie and Pfizer in Humira licensing deal

3 December 2018 AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More on this story

Americas

AbbVie and Mylan agree Humira licensing deal

18 July 2018 US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

Americas

AbbVie and Samsung Bioepis resolve Humira litigation

9 April 2018 AbbVie has secured another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.

Americas

AbbVie and Pfizer in Humira licensing deal

3 December 2018 AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More on this story

Americas

AbbVie and Mylan agree Humira licensing deal

18 July 2018 US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

Americas

AbbVie and Samsung Bioepis resolve Humira litigation

9 April 2018 AbbVie has secured another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.

Americas

AbbVie and Pfizer in Humira licensing deal

3 December 2018 AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.